USPTO published patent application US20260091040A1 on April 2, 2026, covering methods for treating progressive familial intrahepatic cholestasis (PFIC) with ileal bile acid transport (IBAT) inhibitor odevixibat or its pharmaceutically acceptable salts. The application (No. 19334510, filed September 19, 2025) claims methods including reducing mean pruritus score, reducing mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.

This is a patent application publication, not a granted patent or regulatory requirement. Pharmaceutical companies and researchers developing PFIC treatments should review the claims for potential freedom-to-operate concerns or licensing opportunities. No compliance actions or deadlines are associated with this document.